Abstract

Purpura fulminans (PF) is a rare but devastating complication of sepsis characterized by a highly thrombotic subtype of disseminated intravascular coagulation (DIC). A medical emergency, PF often requires the involvement of consultant hematologists to assist with diagnosis and management of patients who are in a highly dynamic and deteriorating clinical situation. Patients who survive past the first 24 to 72 hours often die from complications of unchecked thrombosis rather than shock, and survivors are usually left with severe scarring and tissue loss. Despite these challenging features, PF is a pathophysiologically distinct, homogeneous, and highly predictable form of sepsis-associated DIC for which poor outcomes are not a foregone conclusion. The fundamental pathologic lesion in PF is a failure of the anticoagulant protein C pathway, which leads to uncontrolled microvascular clotting and inadequate protein C–mediated cytoprotective effects, which are vital for survival in sepsis. Herein, we review the clinical features and diagnosis of PF. Drawing from existing clinical literature and recent advances in our understanding of the pathophysiology of PF, we describe rationally designed treatment approaches for this disorder, including repletion of natural circulating anticoagulants, use of therapeutic anticoagulation, and ways to optimize transfusion support, and we outline specific interventions that we would recommend avoiding.

1.
Perera
TB
,
Murphy-Lavoie
HM
. Purpura Fulminans.
StatPearls
.
Treasure Island (FL)
:
StatPearls Publishing
;
July 17, 2023
.
2.
Price
VE
,
Ledingham
DL
,
Krumpel
A
,
Chan
AK
.
Diagnosis and management of neonatal purpura fulminans
.
Semin Fetal Neonatal Med
.
2011
;
16
(
6
):
318
-
322
.
3.
Dreyfus
M
,
Magny
JF
,
Bridey
F
, et al
.
Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate
.
N Engl J Med
.
1991
;
325
(
22
):
1565
-
1568
.
4.
Theron
A
,
Dautremay
O
,
Boissier
E
, et al
.
Idiopathic purpura fulminans associated with anti-protein S antibodies in children: a multicenter case series and systematic review
.
Blood Adv
.
2022
;
6
(
2
):
495
-
502
.
5.
Honjo
O
,
Kubo
T
,
Sugaya
F
, et al
.
Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report
.
J Immunother Cancer
.
2019
;
7
(
1
):
97
.
6.
Wirbel
C
,
Breton
AL
,
Donzier
L
, et al
.
Multi-system involvement-including purpura fulminans-as an adverse effects of immune checkpoint inhibitor therapy for clear cell renal cell carcinoma
.
Lancet
.
2024
;
403
(
10446
):
2818
-
2819
.
7.
Colling
ME
,
Bendapudi
PK
.
Purpura fulminans: mechanism and management of dysregulated hemostasis
.
Transfus Med Rev
.
2018
;
32
(
2
):
69
-
76
.
8.
Darmstadt
GL
.
Acute infectious purpura fulminans: pathogenesis and medical management
.
Pediatr Dermatol
.
1998
;
15
(
3
):
169
-
183
.
9.
Powars
DR
,
Rogers
ZR
,
Patch
MJ
,
McGehee
WG
,
Francis
RB
, et al
.
Purpura fulminans in meningococcemia: association with acquired deficiencies of proteins C and S
.
N Engl J Med
.
1987
;
317
(
9
):
571
-
572
.
10.
Powars
D
,
Larsen
R
,
Johnson
J
, et al
.
Epidemic meningococcemia and purpura fulminans with induced protein C deficiency
.
Clin Infect Dis
.
1993
;
17
(
2
):
254
-
261
.
11.
Faust
SN
,
Levin
M
,
Harrison
OB
, et al
.
Dysfunction of endothelial protein C activation in severe meningococcal sepsis
.
N Engl J Med
.
2001
;
345
(
6
):
408
-
416
.
12.
Lerolle
N
,
Carlotti
A
,
Melican
K
, et al
.
Assessment of the interplay between blood and skin vascular abnormalities in adult purpura fulminans
.
Am J Respir Crit Care Med
.
2013
;
188
(
6
):
684
-
692
.
13.
Bendapudi
PK
,
Robbins
A
,
LeBoeuf
N
, et al
.
Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentrate
.
Blood Adv
.
2018
;
2
(
21
):
2917
-
2921
.
14.
de Kleijn
ED
,
de Groot
R
,
Hack
CE
, et al
.
Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study
.
Crit Care Med
.
2003
;
31
(
6
):
1839
-
1847
.
15.
Ohlin
AK
,
Larsson
K
,
Hansson
M
.
Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma
.
J Thromb Haemost
.
2005
;
3
(
5
):
976
-
982
.
16.
Okamoto
T
,
Tanigami
H
,
Suzuki
K
,
Shimaoka
M
.
Thrombomodulin: a bifunctional modulator of inflammation and coagulation in sepsis
.
Crit Care Res Pract
.
2012
;
2012
:
614545
.
17.
Aikawa
N
,
Shimazaki
S
,
Yamamoto
Y
, et al
.
Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial
.
Shock
.
2011
;
35
(
4
):
349
-
354
.
18.
Saito
H
,
Maruyama
I
,
Shimazaki
S
, et al
.
Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial
.
J Thromb Haemost
.
2007
;
5
(
1
):
31
-
41
.
19.
Girardin
E
,
Grau
GE
,
Dayer
JM
,
Roux-Lombard
P
,
Lambert
PH
.
Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura
.
N Engl J Med
.
1988
;
319
(
7
):
397
-
400
.
20.
Waage
A
,
Halstensen
A
,
Espevik
T
.
Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease
.
Lancet
.
1987
;
1
(
8529
):
355
-
357
.
21.
Lecuyer
H
,
Borgel
D
,
Nassif
X
,
Coureuil
M
.
Pathogenesis of meningococcal purpura fulminans
.
Pathog Dis
.
2017
;
75
(
3
):
1
-
7
.
22.
Hellum
M
,
Øvstebø
R
,
Brusletto
BS
,
Berg
JP
,
Brandtzaeg
P
,
Henriksson
CE
.
Microparticle-associated tissue factor activity correlates with plasma levels of bacterial lipopolysaccharides in meningococcal septic shock
.
Thromb Res
.
2014
;
133
(
3
):
507
-
514
.
23.
Yong
J
,
Toh
CH
.
Rethinking coagulation: from enzymatic cascade and cell-based reactions to a convergent model involving innate immune activation
.
Blood
.
2023
;
142
(
25
):
2133
-
2145
.
24.
Ammollo
CT
,
Semeraro
F
,
Xu
J
,
Esmon
NL
,
Esmon
CT
.
Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation
.
J Thromb Haemost
.
2011
;
9
(
9
):
1795
-
1803
.
25.
Kim
JE
,
Yoo
HJ
,
Gu
JY
,
Kim
HK
.
Histones induce the procoagulant phenotype of endothelial cells through tissue factor up-regulation and thrombomodulin down-regulation
.
PLoS One
.
2016
;
11
(
6
):
e0156763
.
26.
Lewis
LA
,
Ram
S
.
Meningococcal disease and the complement system
.
Virulence
.
2014
;
5
(
1
):
98
-
126
.
27.
Konar
M
,
Granoff
DM
.
Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults
.
Blood
.
2017
;
130
(
7
):
891
-
899
.
28.
Klos
A
,
Tenner
AJ
,
Johswich
KO
,
Ager
RR
,
Reis
ES
,
Köhl
J
.
The role of the anaphylatoxins in health and disease
.
Mol Immunol
.
2009
;
46
(
14
):
2753
-
2766
.
29.
Lehner
PJ
,
Davies
KA
,
Walport
MJ
, et al
.
Meningococcal septicaemia in a C6-deficient patient and effects of plasma transfusion on lipopolysaccharide release
.
Lancet
.
1992
;
340
(
8832
):
1379
-
1381
.
30.
Tesh
VL
,
Duncan
RL
,
Morrison
DC
.
The interaction of Escherichia coli with normal human serum: the kinetics of serum-mediated lipopolysaccharide release and its dissociation from bacterial killing
.
J Immunol
.
1986
;
137
(
4
):
1329
-
1335
.
31.
Brandtzaeg
P
,
Kierulf
P
,
Gaustad
P
, et al
.
Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease
.
J Infect Dis
.
1989
;
159
(
2
):
195
-
204
.
32.
Bendapudi
PK
,
Nazeen
S
,
Ryu
J
, et al
.
Low-frequency inherited complement receptor variants are associated with purpura fulminans
.
Blood
.
2024
;
143
(
11
):
1032
-
1044
.
33.
Warkentin
TE
.
Limb ischemic necrosis secondary to microvascular thrombosis: a brief historical review
.
Semin Thromb Hemost
.
2024
;
50
(
5
):
760
-
772
.
34.
Karki
BR
,
Sedhai
YR
. Bokhari SRA Waterhouse-Friderichsen Syndrome.
StatPearls
.
Treasure Island (FL)
:
StatPearls Publishing
;
June:2023
:
26
.
35.
Veldman
A
,
Fischer
D
,
Wong
FY
, et al
.
Human protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patients
.
Crit Care
.
2010
;
14
(
4
):
R156
.
36.
Smith
OP
,
White
B
.
Infectious purpura fulminans: diagnosis and treatment
.
Br J Haematol
.
1999
;
104
(
2
):
202
-
207
.
37.
Smith
OP
,
White
B
,
Vaughan
D
, et al
.
Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans
.
Lancet
.
1997
;
350
(
9091
):
1590
-
1593
.
38.
Rintala
E
,
Kauppila
M
,
Seppala
OP
, et al
.
Protein C substitution in sepsis-associated purpura fulminans
.
Crit Care Med
.
2000
;
28
(
7
):
2373
-
2378
.
39.
Piccin
A
,
O' Marcaigh
A
,
Mc Mahon
C
, et al
.
Non-activated plasma-derived PC improves amputation rate of children undergoing sepsis
.
Thromb Res
.
2014
;
134
(
1
):
63
-
67
.
40.
Dreyfus
M
,
Masterson
M
,
David
M
, et al
.
Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency
.
Semin Thromb Hemost
.
1995
;
21
(
4
):
371
-
381
.
41.
Ranieri
VM
,
Thompson
BT
,
Barie
PS
, et al
.
Drotrecogin alfa (activated) in adults with septic shock
.
N Engl J Med
.
2012
;
366
(
22
):
2055
-
2064
.
42.
Bernard
GR
,
Vincent
JL
,
Laterre
PF
, et al
.
Efficacy and safety of recombinant human activated protein C for severe sepsis
.
N Engl J Med
.
2001
;
344
(
10
):
699
-
709
.
43.
White
B
,
Livingstone
W
,
Murphy
C
,
Hodgson
A
,
Rafferty
M
,
Smith
OP
.
An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia
.
Blood
.
2000
;
96
(
12
):
3719
-
3724
.
44.
Vincent
JL
,
Nadel
S
,
Kutsogiannis
DJ
, et al
.
Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies
.
Crit Care
.
2005
;
9
(
4
):
R331
-
R343
.
45.
Warren
BL
,
Eid
A
,
Singer
P
, et al
.
Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial
.
JAMA
.
2001
;
286
(
15
):
1869
-
1878
.
46.
Mori
F
,
Angelini
C
,
Farina
C
.
New plasma protein C and protein S concentrate: a synergy for therapeutic purposes
.
Vox Sang
.
2024
;
119
(
3
):
193
-
202
.
47.
Zarychanski
R
,
Abou-Setta
AM
,
Kanji
S
, et al
.
The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis
.
Crit Care Med
.
2015
;
43
(
3
):
511
-
518
.
48.
Antley
RM
,
McMillan
CW
.
Sequential coagulation studies in purpura fulminans
.
N Engl J Med
.
1967
;
276
(
23
):
1287
-
1290
.
49.
Warkentin
TE
.
Ischemic limb gangrene with pulses
.
N Engl J Med
.
2015
;
373
(
24
):
2386
-
2388
.
50.
Di Cera
E
.
Thrombin as procoagulant and anticoagulant
.
J Thromb Haemost
.
2007
;
5
(
suppl 1
):
196
-
202
.
51.
Fragasso
G
,
Corti
A
,
Loiacono
F
,
Margonato
A
,
D'Angelo
A
.
Oral direct thrombin inhibition: a double-edged sword?
.
Heart Lung Vessel
.
2015
;
7
(
3
):
191
-
197
.
52.
Artang
R
,
Rome
E
,
Nielsen
JD
,
Vidaillet
HJ
.
Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors
.
Am J Cardiol
.
2013
;
112
(
12
):
1973
-
1979
.
53.
Perzborn
E
,
Heitmeier
S
,
Buetehorn
U
,
Laux
V
.
Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo
.
J Thromb Haemost
.
2014
;
12
(
7
):
1054
-
1065
.
54.
Warkentin
TE
,
Ning
S
,
Lim
W
.
Colloid transfusion, natural anticoagulant depletion, and symmetric peripheral gangrene
.
N Engl J Med
.
2020
;
383
(
16
):
1592
-
1594
.
55.
Franchini
M
,
Lippi
G
.
Prothrombin complex concentrates: an update
.
Blood Transfus
.
2010
;
8
(
3
):
149
-
154
.
56.
Rumbus
Z
,
Matics
R
,
Hegyi
P
, et al
.
Fever is associated with reduced, hypothermia with increased mortality in septic patients: a meta-analysis of clinical trials
.
PLoS One
.
2017
;
12
(
1
):
e0170152
.
57.
Griffin
JH
,
Zlokovic
BV
,
Mosnier
LO
.
Activated protein C: biased for translation
.
Blood
.
2015
;
125
(
19
):
2898
-
2907
.
You do not currently have access to this content.
Sign in via your Institution